854222--12/7/2006--INDEVUS_PHARMACEUTICALS

related topics

{product, candidate, development}

{stock, price, share}

{product, liability, claim}

{acquisition, growth, future}

{control, financial, internal}

{debt, indebtedness, cash}

{property, intellectual, protect}

{competitive, industry, competition}

{financial, litigation, operation}

{personnel, key, retain}

{provision, law, control}

RISKS RELATED TO OUR BUSINESS We are dependent on SANCTURA. We may not compete successfully in the overactive bladder market. Our product candidates including SANCTURA XR and NEBIDO may not be successfully developed or achieve market acceptance. We rely on the favorable outcome of clinical trials of our product candidates including SANCTURA XR and NEBIDO. We have regulatory and guideline risks. We are dependent on third parties to manufacture SANCTURA and SANCTURA XR. We rely on third parties to commercialize and manufacture our products. Our failure to acquire and develop additional product candidates will impair our ability to grow. We may undertake strategic acquisitions in the future and any difficulties from integrating such acquisitions could adversely affect our stock price, operating results and results of operations. We need additional funds in the future. We have a history of losses and expect losses to continue. We may not be profitable in the future. The outcome of the Redux litigation could materially harm us. We rely on the protection provided by our intellectual property and have limited patent protection on some of our products. We may depend on market exclusivity for certain of our products. Our products may be unable to compete successfully with other products. To be successful, our product candidates must be accepted by the health care community, which can be very slow to adopt or unreceptive to new products. We could be materially harmed if our agreements were terminated. We depend upon key personnel and consultants. We have product liability exposure and insurance uncertainties related to our products. If third parties on which we rely for clinical trials services do not perform as contractually required or as we expect, we may not be able to obtain regulatory approval for or commercialize our product candidates. Risks Related to Our Common Stock and Other Securities We may issue preferred stock with rights that could affect your rights and prevent a takeover of the business. We have never paid any dividends on our common stock. If we pay cash dividends on our common stock, certain holders of our securities may be deemed to have received a taxable dividend without the receipt of any cash. The price for our securities is volatile. The price for our common stock could be negatively affected if we issue additional shares or if third parties exercise registration rights. Our stockholders could be diluted if we issue our shares subject to options, warrants, convertible notes, stock awards or other arrangements. Increased leverage as a result of our convertible debt offering may harm our financial condition and results of operations.

Full 10-K form ▸

854222--12/7/2006--INDEVUS_PHARMACEUTICALS_INC